A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirepemat (Primary)
Indications Dementia; Parkinson's disease
Focus Adverse reactions; Proof of concept
Sponsors Integrative Research Laboratories

Most Recent Events

12 Mar 2020 Results published in the Movement Disorders
23 Sep 2019 According to an Integrative Research Laboratories media release, results from this trial will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders in Nice, France.
16 Nov 2018 Status changed from recruiting to completed.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight